Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang S.H. | - |
dc.contributor.author | Yoo M.R. | - |
dc.contributor.author | Park C.H. | - |
dc.contributor.author | Jeon T.J. | - |
dc.contributor.author | Kim S.J. | - |
dc.contributor.author | Kim T.H. | - |
dc.date.available | 2020-11-02T22:43:37Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0938-7994 | - |
dc.identifier.issn | 1432-1084 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/11367 | - |
dc.description.abstract | Objectives: To compare tumour enhancement patterns measured using dynamic contrast-enhanced (DCE)-CT with tumour metabolism measured using positron emission tomography (PET)-CT in patients with non-small cell lung cancer (NSCLC) and stable disease after chemotherapy or chemoradiotherapy. Methods: After treatment, 75 NSCLC tumours in 65 patients who had stable disease on DCE-CT according to Response Evaluation Criteria in Solid Tumour (RECIST) were evaluated using PET-CT. On DCE-CT, relative enhancement ratios (RER) of tumour at 30, 60, 90, 120 s and 5 min after injection of contrast material were measured. Metabolic responses of tumours were classified into two groups according to the maximum standardized uptake value (SUVmax) by PET-CT: complete metabolic response (CR) with an SUVmax of less than 2.5, and noncomplete metabolic response (NR) with an SUVmax of at least 2.5. Results: Using the optimal RER60 cutoff value of 43.7 % to predict NR of tumour gave 95.7 % sensitivity, 64.2 % specificity, and 82.1 % positive and 95.0 % negative predictive values. After adjusting for tumour size, the odds ratio for NR in tumour with an RER60 of at least 43.7 % was 70.85 (95 % CI = 7.95-630.91; P < 0.05). Conclusions: Even when disease was stable according to RECIST, DCE-CT predicted hypermetabolic status of residual tumour in patients with NSCLC after treatment. Key Points: • Dynamic contrast-enhanced CT (DCE-CT) can provide useful metabolic information about non-small cell lung cancer. • NSCLC lesions, even grossly stable after treatment, show various metabolic states. • DCE-CT enhancement patterns correlate with tumour metabolic status as shown by PET. • DCE-CT helps to assess hypermetabolic NSCLC as stable disease after treatment. © 2013 European Society of Radiology. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1007/s00330-012-2755-0 | - |
dc.identifier.scopusid | 2-s2.0-84878688057 | - |
dc.identifier.bibliographicCitation | European Radiology, v.23, no.6, pp 1573 - 1581 | - |
dc.citation.title | European Radiology | - |
dc.citation.volume | 23 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1573 | - |
dc.citation.endPage | 1581 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | contrast medium | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | advanced cancer | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer size | - |
dc.subject.keywordPlus | chemoradiotherapy | - |
dc.subject.keywordPlus | computer assisted tomography | - |
dc.subject.keywordPlus | contrast enhancement | - |
dc.subject.keywordPlus | diagnostic accuracy | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human tissue | - |
dc.subject.keywordPlus | lung non small cell cancer | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metabolism | - |
dc.subject.keywordPlus | positron emission tomography | - |
dc.subject.keywordPlus | predictive value | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Aged, 80 and over | - |
dc.subject.keywordPlus | Area Under Curve | - |
dc.subject.keywordPlus | Carcinoma, Non-Small-Cell Lung | - |
dc.subject.keywordPlus | Chemoradiotherapy | - |
dc.subject.keywordPlus | Contrast Media | - |
dc.subject.keywordPlus | Drug Therapy | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Fluorodeoxyglucose F18 | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Image Processing, Computer-Assisted | - |
dc.subject.keywordPlus | Lung Neoplasms | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Odds Ratio | - |
dc.subject.keywordPlus | Positron-Emission Tomography | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Sensitivity and Specificity | - |
dc.subject.keywordPlus | Time Factors | - |
dc.subject.keywordPlus | Tomography, X-Ray Computed | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordAuthor | 18F-fluoro- deoxyglucose positron emission tomography | - |
dc.subject.keywordAuthor | Computed tomography | - |
dc.subject.keywordAuthor | Enhancement pattern | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Standardized uptake value | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.